Fenebrutinib Reduces Disease Activity in a Mouse Model of Inflammatory Multiple Sclerosis Associated With Reduced Microglial Activation
T cells, B cells and myeloid lineage cells may drive acute and chronic inflammation in multiple sclerosis (MS). Bruton’s tyrosine kinase (BTK) is active in both B cell and myeloid lineage cell signaling, making it an attractive therapeutic target for MS. This study investigated treatment with fenebrutinib, a selective inhibitor of BTK, in experimental autoimmune encephalitis, a mouse model of chronic inflammatory MS with minimal B-cell involvement.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.